TAT-TRPV1 (736-745) inhibits the interaction of TRPV1 and AKAP79. TAT-TRPV1 (736-745) is a TRPV1 antagonist and useful for inflammation and hyperalgesia study.
Catalogue number crb1001171 Molecular Weight 2927.6 Sequence (one letter code)
Sequence (three letter code)
Aliase 736-745-TAT Purity >95% Storage -20°C References
Btesh et al., (2013). Mapping the binding site of TRPV1 on AKAP79: implications for inflammatory hyperalgesia. J Neurosci., 33(21): 9184. doi: 10.1523/JNEUROSCI.4991-12.2013.
Zhang et al., (2008). Proinflammatory mediators modulate the heat-activated ion channel TRPV1 via the scaffolding protein AKAP79/150. Neuron, 59(3): 450. doi: 10.1016/j.neuron.2008.05.015.
Manufactured in: United Kingdom
TAT-TRPV1 (736-745) is a cell-permeable TRPV1 fragment (capsaicin receptor and the vanilloid receptor 1), that can inhibit the interaction of TRPV1 and A-kinase anchoring protein 79 (AKAP79). TAT- TRPV1 (736-745) consists of amino acids 736-749 from the TRPV1 C-terminal domain, combined with amino acids 47–57 of TAT to promote uptake across neuronal cell membranes. TAT-TRPV1 (736-745) inhibits both the first and the second phase of pain behaviour in the formalin test, implying an effect on both acute and inflammatory pain.
A-kinase anchoring protein 79 (AKAP79) is a protein that targets kinases to TRPV1. Inflammation causes hyperalgesia but can be reduced when TRPV1 is blocked. a key region on AKAP79, amino acids 326–336, is responsible for its interaction with TRPV1. TAT-TRPV1 (736-745) promotes uptake across the cell membrane and TRPV1 (736-745) inhibited inflammatory hyperalgesia in mice. TAT-TRPV1 (736-745) did not affect pain thresholds in the absence of inflammation. These results suggest that antagonizing the TRPV1–AKAP79 interaction will be a useful strategy for inhibiting inflammatory hyperalgesia and TAT is an effective delivery system.